SCHEMBL259261

SCHEMBL259261

CCOC(=O)c1oc2ncccc2c1NC(=O)c1ccnc(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 13/20 0.50
HSD17B10 Q99714 9/20 0.50
TSHR P16473 8/20 0.50
ALDH1A1 P00352 7/20 0.50
HPGD P15428 6/20 0.50
MAPT P10636 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
CYP1A2 P05177 3/20 0.49
CYP3A4 P08684 3/20 0.49
NPSR1 Q6W5P4 3/20 0.49
CYP2D6 P10635 2/20 0.49
CYP2C19 P33261 2/20 0.49
CYP2C9 P11712 2/20 0.49
USP2 O75604 1/20 0.49
ALOX15 P16050 1/20 0.44
LMNA P02545 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14581998 0.86 HTT (0.57) KDM4EHSD17B10TSHRALDH1A1HPGD
SCHEMBL259376 0.84 ALDH1A1 (0.41) KDM4EALDH1A1HPGDMAPTL3MBTL1
SCHEMBL13298498 0.83 HPGD (0.72) KDM4EHSD17B10TSHRALDH1A1HPGD
SCHEMBL259094 0.83 ALDH1A1 (0.46) KDM4EHSD17B10TSHRALDH1A1HPGD
SCHEMBL13102749 0.83 LMNA (0.51) KDM4EHSD17B10TSHRALDH1A1HPGD
SCHEMBL259251 0.82 KDM4E (0.58) KDM4EHSD17B10TSHRALDH1A1HPGD
SCHEMBL13318503 0.81 KDM4E (0.49) KDM4EHSD17B10TSHRALDH1A1HPGD
SCHEMBL259197 0.80 KDM4E (0.50) KDM4EHSD17B10TSHRALDH1A1HPGD
SCHEMBL259367 0.77 KDM4E (0.73) KDM4EHSD17B10TSHRALDH1A1HPGD
SCHEMBL259186 0.76 RAB9A (0.47) KDM4EHSD17B10TSHRALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A KDM4E 2196/4885HSD17B10 1278/4885TSHR 4005/4885
US-20070037805-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A KDM4E 2196/4885HSD17B10 1278/4885TSHR 4005/4885
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A KDM4E 2196/4885HSD17B10 1278/4885TSHR 4005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.